NASDAQ:NRSN NeuroSense Therapeutics (NRSN) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free NRSN Stock Alerts $1.33 +0.06 (+4.72%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$1.19▼$1.3450-Day Range$1.23▼$2.1152-Week Range$0.40▼$2.33Volume136,632 shsAverage Volume171,568 shsMarket Capitalization$18.18 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get NeuroSense Therapeutics alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About NeuroSense Therapeutics Stock (NASDAQ:NRSN)NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.Read More NRSN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRSN Stock News HeadlinesMay 4, 2024 | americanbankingnews.comNeuroSense Therapeutics (NASDAQ:NRSN) Shares Up 4.7%May 2, 2024 | prnewswire.comNeuroSense Announces First Quarter 2024 Business UpdateMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.April 22, 2024 | finance.yahoo.comNeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseaseApril 19, 2024 | investing.comNeuroSense reports positive ALS trial results, trends in biomarkersApril 18, 2024 | prnewswire.comNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingApril 12, 2024 | finance.yahoo.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024April 12, 2024 | prnewswire.comNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024May 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.April 10, 2024 | prnewswire.comNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private PlacementApril 9, 2024 | markets.businessinsider.comNeuroSense Joins With Lonza To Advance Neurodegenerative Disease Treatments; Stock Up In Pre-marketApril 9, 2024 | prnewswire.comNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and DiagnosticsApril 7, 2024 | uk.investing.comNeuroSense reports significant ALS trial results, year-end financialsApril 5, 2024 | investorplace.comNRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023April 5, 2024 | finance.yahoo.comNeuroSense Announces Year End 2023 Financial Results and Provides Business UpdateMarch 23, 2024 | morningstar.comNeuroSense Therapeutics Ltd NRSNFebruary 21, 2024 | finance.yahoo.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 21, 2024 | prnewswire.comNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM TrialFebruary 7, 2024 | finance.yahoo.comNeuroSense Regains Compliance with NASDAQ Minimum Bid Price RuleJanuary 30, 2024 | finanznachrichten.deNeuroSense Therapeutics Ltd: NeuroSense's ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 30, 2024 | finance.yahoo.comNeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024January 9, 2024 | finance.yahoo.comNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 CatalystsJanuary 4, 2024 | finance.yahoo.comNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementDecember 19, 2023 | investing.comNeurosense Therapeutics (NRSN) Earnings Dates & ReportsDecember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Neurosense Therapeutics Ltd. (NRSN)December 14, 2023 | finance.yahoo.comNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS TrialDecember 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Neurosense Therapeutics Ltd. (NRSN), Cerevel Therapeutics Holdings (CERE)See More Headlines Receive NRSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/05/2024Today5/05/2024Next Earnings (Estimated)6/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRSN CUSIPN/A CIK1875091 Webwww.neurosense-tx.com Phone972-9799-6183FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-678.59% Return on Assets-207.30% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-9.50Miscellaneous Outstanding Shares13,670,000Free Float9,922,000Market Cap$18.18 million OptionableNot Optionable Beta1.73 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Or Eisenberg (Age 43)Chief Financial Officer Comp: $382kDr. Ferenc Tracik M.D. (Age 60)Chief Medical Officer Comp: $532kMr. Alon Ben-Noon (Age 45)Co-Founder, CEO & Director Comp: $619kMs. Hagit Binder (Age 46)Chief Operation Officer Dr. Niva Russek-Blum Ph.D. (Age 45)Chief Technology Officer Ms. Yael Barak (Age 54)VP of Quality & Compliance Ms. Keren PushettHead of HRMr. Eidan LoushiC.R.A.More ExecutivesKey CompetitorsIndaptus TherapeuticsNASDAQ:INDPGalectoNASDAQ:GLTOAptorum GroupNASDAQ:APMVincerx PharmaNASDAQ:VINCAvalo TherapeuticsNASDAQ:AVTXView All Competitors NRSN Stock Analysis - Frequently Asked Questions Should I buy or sell NeuroSense Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks. How have NRSN shares performed in 2024? NeuroSense Therapeutics' stock was trading at $0.7850 on January 1st, 2024. Since then, NRSN stock has increased by 69.4% and is now trading at $1.33. View the best growth stocks for 2024 here. Are investors shorting NeuroSense Therapeutics? NeuroSense Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 88,400 shares, an increase of 38.8% from the March 31st total of 63,700 shares. Based on an average daily volume of 308,000 shares, the short-interest ratio is currently 0.3 days. Approximately 0.8% of the company's stock are sold short. View NeuroSense Therapeutics' Short Interest. When is NeuroSense Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our NRSN earnings forecast. How were NeuroSense Therapeutics' earnings last quarter? NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) announced its quarterly earnings data on Friday, April, 5th. The company reported ($0.16) earnings per share (EPS) for the quarter. When did NeuroSense Therapeutics IPO? NeuroSense Therapeutics (NRSN) raised $13 million in an initial public offering on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share. How do I buy shares of NeuroSense Therapeutics? Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRSN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsAutomatic Income (from home)Awesomely, LLCCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmithWarren Buffet Stockpiling Gold?Reagan Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
